Traumatic Brain Injury - Pipeline Review, H2 2019

Traumatic Brain Injury - Pipeline Review, H2 2019

Summary

latest Pharmaceutical and Healthcare disease pipeline guide Traumatic Brain Injury - Pipeline Review, H2 2019, provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape.

Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimers disease and coordination problems.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 8, 8, 1, 89 and 15 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.

Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Introduction
Traumatic Brain Injury - Overview
Traumatic Brain Injury - Therapeutics Development
Traumatic Brain Injury - Therapeutics Assessment
Traumatic Brain Injury - Companies Involved in Therapeutics Development
Traumatic Brain Injury - Drug Profiles
Traumatic Brain Injury - Dormant Projects
Traumatic Brain Injury - Discontinued Products
Traumatic Brain Injury - Product Development Milestones
Appendix

List Of Tables


Number of Products under Development for Traumatic Brain Injury, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Traumatic Brain Injury - Pipeline by Acelerox LLC, H2 2019
Traumatic Brain Injury - Pipeline by ALSP Inc, H2 2019
Traumatic Brain Injury - Pipeline by AlzeCure Pharma AB, H2 2019
Traumatic Brain Injury - Pipeline by AMAG Pharmaceuticals Inc, H2 2019
Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings Inc, H2 2019
Traumatic Brain Injury - Pipeline by Anagin Inc, H2 2019
Traumatic Brain Injury - Pipeline by Anida Pharma Inc, H2 2019
Traumatic Brain Injury - Pipeline by Annovis Bio Inc, H2 2019
Traumatic Brain Injury - Pipeline by AntiRadical Therapeutics LLC, H2 2019
Traumatic Brain Injury - Pipeline by Anvyl LLC, H2 2019
Traumatic Brain Injury - Pipeline by Aptinyx Inc, H2 2019
Traumatic Brain Injury - Pipeline by Astrocyte Pharmaceuticals Inc, H2 2019
Traumatic Brain Injury - Pipeline by Athersys Inc, H2 2019
Traumatic Brain Injury - Pipeline by Avanir Pharmaceuticals Inc, H2 2019
Traumatic Brain Injury - Pipeline by Bessor Pharma LLC, H2 2019
Traumatic Brain Injury - Pipeline by Beyond Barriers Therapeutics Inc, H2 2019
Traumatic Brain Injury - Pipeline by Biogen Inc, H2 2019
Traumatic Brain Injury - Pipeline by BioIncept LLC, H2 2019
Traumatic Brain Injury - Pipeline by Bioquark Inc, H2 2019
Traumatic Brain Injury - Pipeline by Brain-Gen LLC, H2 2019
Traumatic Brain Injury - Pipeline by CalciMedica Inc, H2 2019
Traumatic Brain Injury - Pipeline by CavoGene LifeSciences, H2 2019
Traumatic Brain Injury - Pipeline by CellCure, H2 2019
Traumatic Brain Injury - Pipeline by Cellvation Inc, H2 2019
Traumatic Brain Injury - Pipeline by CereSpir Inc, H2 2019
Traumatic Brain Injury - Pipeline by Chimerix Inc, H2 2019
Traumatic Brain Injury - Pipeline by Cognosci Inc, H2 2019
Traumatic Brain Injury - Pipeline by Complement Pharma BV, H2 2019
Traumatic Brain Injury - Pipeline by Deha Pharmaceutical LLC, H2 2019
Traumatic Brain Injury - Pipeline by Eisai Co Ltd, H2 2019
Traumatic Brain Injury - Pipeline by Epigen Biosciences Inc, H2 2019
Traumatic Brain Injury - Pipeline by Fortuna Fix Inc, H2 2019
Traumatic Brain Injury - Pipeline by GABA Therapeutics Inc, H2 2019
Traumatic Brain Injury - Pipeline by GNT Pharma Co Ltd, H2 2019
Traumatic Brain Injury - Pipeline by Hemarina SA, H2 2019
Traumatic Brain Injury - Pipeline by Hibernaid Inc, H2 2019
Traumatic Brain Injury - Pipeline by Hillhurst Biopharmaceuticals Inc, H2 2019
Traumatic Brain Injury - Pipeline by Hope Biosciences LLC, H2 2019
Traumatic Brain Injury - Pipeline by Hoverink Biotechnologies Inc, H2 2019
Traumatic Brain Injury - Pipeline by ImmunoChem Therapeutics LLC, H2 2019
Traumatic Brain Injury - Pipeline by Impression Healthcare Ltd, H2 2019
Traumatic Brain Injury - Pipeline by Inflammatory Response Research Inc, H2 2019
Traumatic Brain Injury - Pipeline by International Stem Cell Corp, H2 2019
Traumatic Brain Injury - Pipeline by Ischemix Inc, H2 2019
Traumatic Brain Injury - Pipeline by JT Pharmaceuticals Inc, H2 2019
Traumatic Brain Injury - Pipeline by Kalytera Therapeutics Inc, H2 2019
Traumatic Brain Injury - Pipeline by KannaLife Sciences Inc, H2 2019
Traumatic Brain Injury - Pipeline by LA Cell Inc, H2 2019
Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals Inc, H2 2019
Traumatic Brain Injury - Pipeline by Mapreg SAS, H2 2019
Traumatic Brain Injury - Pipeline by Mercaptor Discoveries Inc, H2 2019
Traumatic Brain Injury - Pipeline by MetVital Inc, H2 2019
Traumatic Brain Injury - Pipeline by NeuExcell Therapeutics Inc, H2 2019
Traumatic Brain Injury - Pipeline by NeurAegis Inc, H2 2019
Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Ltd, H2 2019
Traumatic Brain Injury - Pipeline by NeurExo Sciences LLC, H2 2019
Traumatic Brain Injury - Pipeline by Neurodon LLC, H2 2019
Traumatic Brain Injury - Pipeline by Neuronasal LLC, H2 2019
Traumatic Brain Injury - Pipeline by NeuroNascent Inc, H2 2019
Traumatic Brain Injury - Pipeline by Neurotrope Bioscience Inc, H2 2019
Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H2 2019
Traumatic Brain Injury - Pipeline by New World Laboratories Inc, H2 2019
Traumatic Brain Injury - Pipeline by NoNO Inc, H2 2019
Traumatic Brain Injury - Pipeline by NuvOx Pharma LLC, H2 2019
Traumatic Brain Injury - Pipeline by Nyrada Inc, H2 2019
Traumatic Brain Injury - Pipeline by Orpheris Inc, H2 2019
Traumatic Brain Injury - Pipeline by Oxeia Biopharmaceuticals Inc, H2 2019
Traumatic Brain Injury - Pipeline by Peptron Inc, H2 2019
Traumatic Brain Injury - Pipeline by PharmatrophiX Inc, H2 2019
Traumatic Brain Injury - Pipeline by Praetego Inc, H2 2019
Traumatic Brain Injury - Pipeline by Prevacus Inc, H2 2019
Traumatic Brain Injury - Pipeline by ProNeurogen Inc, H2 2019
Traumatic Brain Injury - Pipeline by ProThera Biologics Inc, H2 2019
Traumatic Brain Injury - Pipeline by Qrons Inc, H2 2019
Traumatic Brain Injury - Pipeline by Radikal Therapeutics Inc, H2 2019
Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2019
Traumatic Brain Injury - Pipeline by Resolys Bio Inc, H2 2019
Traumatic Brain Injury - Pipeline by RHNanopharmacuticals LLC, H2 2019
Traumatic Brain Injury - Pipeline by Rubicon Biotechnology Inc, H2 2019
Traumatic Brain Injury - Pipeline by SanBio Inc, H2 2019
Traumatic Brain Injury - Pipeline by Seneca Biopharma Inc, H2 2019
Traumatic Brain Injury - Pipeline by Shinkei Therapeutics LLC, H2 2019
Traumatic Brain Injury - Pipeline by Silver Creek Pharmaceuticals Inc, H2 2019
Traumatic Brain Injury - Pipeline by Spinogenix Inc, H2 2019
Traumatic Brain Injury - Pipeline by STATegics Inc, H2 2019
Traumatic Brain Injury - Pipeline by Stemedica Cell Technologies Inc, H2 2019
Traumatic Brain Injury - Pipeline by Swedish Orphan Biovitrum AB, H2 2019
Traumatic Brain Injury - Pipeline by Tellus Therapeutics Inc, H2 2019
Traumatic Brain Injury - Pipeline by Tetra Therapeutics, H2 2019

List Of Figures


Number of Products under Development for Traumatic Brain Injury, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019

Traumatic Brain Injury - Pipeline Review, H2 2019

Traumatic Brain Injury - Pipeline Review, H2 2019latest Pharmaceutical and Healthcare disease pipeline guide Traumatic Brain Injury - Pipeline Review, H2 2019, provides an overview of the Traumatic Brain Injury

USD 2000 View Report

Global Traumatic Brain Injury Therapeutics Market Research Report 2020-2024

Traumatic brain injury (TBI) is a condition in which the brain is injured by external forces such as accidents, sports injuries, and sometimes physical aggression. In the context of China-US

USD 2850 View Report

Global Traumatic Brain Injury Therapeutics Market Research Report 2020-2024

Traumatic brain injury (TBI) is a condition in which the brain is injured by external forces such as accidents, sports injuries, and sometimes physical aggression. In the context of China-US

USD 2850 View Report

Global Traumatic Brain Injuries Treatment Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Traumatic Brain Injuries Treatment is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by

USD 4000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available